Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Annals of Oncology

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1008296622469PMID 9602258
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.

  1997cited by this paper
• Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma : A randomized multicenter study

  1996cited by this paper
• Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.

  1996cited by this paper
• Cisplatin-associated anemia: an erythropoietin deficiency syndrome.

  1995cited by this paper
• Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.

  1995cited by this paper
• Recombinant human erythropoietin and the anemia of cancer.

  1994cited by this paper
• Guidelines for the use of recombinant human erythropoietin.

  1994cited by this paper
• Erythropoietin for anaemia in cancer patients.

  1993cited by this paper
• Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors.

  1993cited by this paper
• EFFECT OF INFLAMMATORY CYTOKINES ON HYPOXIA-INDUCED ERYTHROPOIETIN PRODUCTION

  1992cited by this paper
• Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial.

  1992cited by this paper
• Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.

  1992cited by this paper
• Effect of inflammatory cytokines on hypoxia-induced erythropoietin production.

  1992cited by this paper
• Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.

  1992cited by this paper
• Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production

  1992cited by this paper
• Recombinant human erythropoietin in the treatment of the anaemia of cancer.

  1992cited by this paper
• Chemotherapy-induced anemia.

  1991cited by this paper
• Inappropriate increase in erythropoietin titers during chemotherapy

  1989cited by this paper
• Special report: transfusion risks.

  1987cited by this paper
• Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

  1987cited by this paper
• Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

  1986cited by this paper
• Toxic effects of cis-dichlorodiammineplatinum(II) in man.

  1979cited by this paper

• Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP

  2022cites this paper
• Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.

  2022cites this paper
• Recombinant Human Erythropoietin in Children with Solid Tumors and Chemotherapy-induced Anemia

  2018cites this paper
• Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients

  2017cites this paper
• The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.

  2016cites this paper
• Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells

  2016cites this paper
• Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy

  2015cites this paper
• Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey.

  2014cites this paper
• The Effects of Anemia and Blood Transfusion on Patients With Stage III-IV Ovarian Cancer

  2013cites this paper
• Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents.

  2013cites this paper
• Protective effects of erythropoietin on endotoxin-related organ injury in rats

  2013cites this paper
• Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia

  2012cites this paper
• Treatment of Chemotherapy-Induced Anemia in Ovarian Cancer Patients: Does the Use of Erythropoiesis-Stimulating Agents Worsen Survival?

  2012cites this paper
• Erythropoietin or darbepoetin for patients with cancer.

  2012cites this paper
• Epoetin Beta

  2012cites this paper
• Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy.

  2011cites this paper
• Population-Based Analysis of the Frequency of Anemia and its Management Before and During Chemotherapy in Patients With Malignant Lymphoma

  2010cites this paper
• Époétine bêta dans le traitement de l'anémie liée à la chimiothérapie dans les tumeurs solides et les hémopathies malignes. Résultats d'un essai clinique, en ouvert, multicentrique

  2010cites this paper
• Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

  2010cites this paper
• [Epoetin beta for the treatment of chemotherapy-induced anaemia in solid and haematological malignancies. Results of an open-label, multicentric clinical trial].

  2010cites this paper
• [Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors].

  2009cites this paper
• Recombinant human epoetin beta in the treatment of chemotherapy-related anemia

  2009cites this paper
• Epoetin-β treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events

  2009influential citation
• Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

  2009cites this paper
• Efficacité de l’époétine bêta hebdomadaire dans l’anémie des tumeurs solides sous chimiothérapie

  2009cites this paper
• Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

  2009cites this paper
• Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

  2009cites this paper
• Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

  2009cites this paper
• Effect of treatment with epoetin-β on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients

  2008cites this paper
• Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.

  2008cites this paper
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cites this paper
• Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.

  2008cites this paper
• Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.

  2008cites this paper
• rhEPO in anemic patients with solid tumors and chemotherapy — efficacy and safety

  2008cites this paper
• Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.

  2008cites this paper
• Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent study.

  2008cites this paper
• Effects of rhEPO on quality of life in anemic cancer patients

  2008cites this paper
• Impact of anemia and red blood cell transfusion on organ function

  2008cites this paper
• Epoetin β Once-Weekly Therapy in Anemic Patients with Solid Tumors and Non-Myeloid Hematological Malignancies Receiving Chemotherapy

  2008cites this paper
• Prediction of response to rhEPO in the anemia of cancer

  2008cites this paper
• Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment

  2008cites this paper
• The role of epoetin beta in the treatment of anaemia in patients with gynaecological malignancies.

  2007cites this paper
• A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.

  2007cites this paper
• Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins

  2007cites this paper
• Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy.

  2007cites this paper
• Epoetin beta in oncology: examining the current evidence.

  2006cites this paper
• Treating anaemia: deconstructing healthcare costs

  2006cites this paper
• Optimising the response to epoetin beta for the treatment of cancer-related anaemia

  2006cites this paper
• Pharmacokinetics of Darbepoetin Alfa after Intravenous or Subcutaneous Administration in Patients with Non-myeloid Malignancies Undergoing Chemotherapy

  2006cites this paper
• Pathogenese und Therapie der therapie- und tumorbedingten Anämie

  2006cites this paper
• Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer

  2006cites this paper
• Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.

  2006cites this paper
• Effect of treatment with epoetin Beta on thromboembolic events in anemic patients with cancer: a metaanalysis.

  2006cites this paper
• Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis.

  2006cites this paper
• Cancer-related anemia and recombinant human erythropoietin—an updated overview

  2006cites this paper
• Epoetin beta therapy in patients with solid tumours.

  2006cites this paper
• Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis

  2006cites this paper
• Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

  2006cites this paper
• Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

  2005cites this paper
• Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.

  2005cites this paper
• Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.

  2005cites this paper
• Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.

  2005cites this paper
• Anaemia Management Strategies: Optimising Treatment Using Epoetin Beta (NeoRecormon®)

  2005cites this paper
• Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

  2005cites this paper
• Prävention und Therapie der Anämie bei Tumorpatienten mit Epoetin beta (NeoRecormon®)

  2005cites this paper
• [Anemia in head and neck cancers].

  2005cites this paper
• The Value of Erythropoietin Therapy in Cancer Patients

  2005cites this paper
• Recombinant human erythropoietin in oncology: current status and further developments.

  2005cites this paper
• Management of anaemia in patients with breast cancer: role of epoetin.

  2005cites this paper
• Hematopoietic Growth Factors in Lung Cancer

  2004cites this paper
• EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.

  2004influential citation
• [Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology - Update 2003].

  2004cites this paper
• Evolving Treatment Strategies for Anaemia in Cancer: Experience with Epoetin Beta

  2004cites this paper
• Role of epoetin in the management of anaemia in patients with lung cancer.

  2004cites this paper
• Comparison of Clinical Outcomes of Different Erythropoietin Usage Strategies

  2004cites this paper
• Erythropoietin for patients with malignant disease.

  2004cites this paper
• Optimising Anaemia Management with Epoetin Beta

  2004cites this paper
• Bone Marrow Stroma Damage Induced by Chemotherapy for Acute Lymphoblastic Leukemia in Children

  2004cites this paper
• Chapter 47 – Management of Complications of Chemotherapy

  2004cites this paper
• Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.

  2004cites this paper
• Systemic chemotherapy in elderly patients with locally advanced and/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and role of recombinant human erythropoietin.

  2003cites this paper
• Prevention of Anemia in Patients with Solid Tumors Receiving Platinum-Based Chemotherapy by Recombinant Human Erythropoietin (rHuEpo): A Prospective, Open Label, Randomized Trial by the Hellenic Cooperative Oncology Group

  2003cites this paper
• A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.

  2003cites this paper
• Therapie mit Erythropoetinen in der Onkologie

  2003cites this paper
• The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy

  2003cites this paper
• Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy—results of a randomized trial

  2003cites this paper
• KEEPING CANCER GUIDELINES CURRENT: RESULTS OF A COMPREHENSIVE PROSPECTIVE LITERATURE MONITORING STRATEGY FOR TWENTY CLINICAL PRACTICE GUIDELINES

  2003cites this paper
• Overview of Cancer‐Related Anemia: Focus on the Potential Role of Darbepoetin alfa

  2002cites this paper
• Predictive factors for response of anemia to recombinant human erythropoietin

  2002cites this paper
• Effects of treatment with rhEPO on quality of life in anemic cancer patients

  2002cites this paper
• [General principles of treatment of anemia in cancer patients].

  2002cites this paper
• Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

  2002cites this paper
• Erythropoietin, uncertainty principle and cancer related anaemia

  2002cites this paper
• Impact of anemia on organ functions

  2002cites this paper
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cites this paper
• Systematic review of controlled trials on erythropoietin to support evidence-based guidelines.

  2002influential citation
• Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.

  2002cites this paper
• rhEPO in anemia associated with solid tumors and chemotherapy

  2002cites this paper
• Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation.

  2002cites this paper
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cites this paper